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The leukocyte cell-surface antigen CD38 is the major
nicotinamide adenide dinucleotide glycohydrolase in
mammals, and its ectoenzyme activity is involved in
calcium mobilization. CD38 is also a raft-dependent
signaling molecule. CD38 forms a tetramer on the
cell surface, but the structural basis and the func-
tional significance of tetramerization have remained
unexplored. We identified the interfaces contributing
to the homophilic interaction of mouse CD38 by site-
specific crosslinking on the cell surface with an
expanded genetic code, based on a crystallographic
analysis. A combination of the three interfaces
enables CD38 to tetramerize: one interface involving
the juxtamembrane a-helix is responsible for the
formation of the core dimer, which is further dimer-
ized via the other two interfaces. This dimerization
of dimers is required for the catalytic activity and
the localization of CD38 in membrane rafts. The
glycosylation prevents further self-association of
the tetramer. Accordingly, the tetrameric interaction
underlies the multifaceted actions of CD38.
INTRODUCTION
The leukocyte cell-surface antigen CD38 is a glycoprotein,
composed of a large extracellular domain, a transmembraneStructure 20, 1585–15domain, and a short cytoplasmic domain (Jackson and Bell,
1990). The extracellular domain of CD38 contains the catalytic
nicotinamide adenide dinucleotide (NAD+) glycohydrolase
(Gelman et al., 1993; Kontani et al., 1993), which is the main
NAD+ glycohydrolase in mammalian cells (Cockayne et al.,
1998). The cleavage of the N-glycoside linkage of NAD+ or nico-
tinamide adenine dinucleotide phosphate (NADP+) generates
ADP-ribose/cyclic ADP-ribose from NAD+ and nicotinic acid
adenine dinucleotide phosphate from NADP+ (Malavasi et al.,
2008). All of these products are able to trigger intracellular
calcium mobilization in an inositol trisphosphate-independent
manner, and CD38 thereby plays a role in calcium-mediated
signaling (Lee, 1994, 2005). The catalytic activity of CD38 is
required in various processes, such as insulin secretion (Kato
et al., 1999; Takasawa et al., 1993), intracellular calcium oscilla-
tion (Fukushi et al., 2001), neutrophil chemotaxis (Partida-
Sa´nchez et al., 2001), dendritic cell trafficking (Partida-Sa´nchez
et al., 2004), and oxytocin secretion (Jin et al., 2007). CD38 is
also involved in the development of diet-induced obesity via
the activation of sirtuins, which are NAD+-dependent deacety-
lases (Aksoy et al., 2006).
On the other hand, CD38 is concentrated in specialized
membrane regions, such as the immunologic synapse (Mun˜oz
et al., 2008) and membrane rafts (Malavasi et al., 2008). CD38
reportedly associates with various supramolecular complexes
within membrane rafts in T cells (CD38/CD3/Lck/LAT) (Zubiaur
et al., 1997), B cells (CD38/BCR/CD19/CD81) (Deaglio et al.,
2003, 2007), natural killer cells (CD38/CD16) (Deaglio et al.,
2002), monocytes (CD38/major histocompatibility complex
[MHC] Class II/CD9) (Zilber et al., 2005), and mature dendritic95, September 5, 2012 ª2012 Elsevier Ltd All rights reserved 1585
Figure 1. Dimer Structure of the Isolated
Extracellular Domain of CD38 in Solution
(A and B) Sedimentation velocity experiments (A)
and size-exclusion chromatography (B) were
performed with the extracellular domain of CD38,
without (full length [FL], black line, FLAG-tag at the
N-terminal) or with the C-terminal truncation (D16,
blue line, FLAG-tag at the N-terminal) or the G68E
mutation (red line, FLAGx3-tag at the N-terminal),
as described in the Supplemental Experimental
Procedures.
(B and C) The extracellular domain of CD38
(0.1 mg/ml) was incubated in the absence and the
presence of 200 mM BS3 at room temperature for
2 hr. The proteins (2 mg each) were then subjected
to 9% SDS-PAGE under reducing conditions and
silver-stained (C). The presence of two bands
without BS3 is due to high-mannose moieties. See
also Figure S1.
Structure
Tetramerization of CD38 on the Cell Surfacecells (CD38/CD83/CD11b/CD81) (Frasca et al., 2006). The asso-
ciation of CD38 with membrane rafts is independent of the cata-
lytic activity of CD38 (Lund et al., 2006, 1999; Manjarrez-Ordun˜o
et al., 2007) and may be involved in the initiation of CD38-
mediated signaling to trigger cell activation and proliferation.
The overall topology of the extracellular domain of human
CD38 (Liu et al., 2005) is similar to those of the other members
of the ADP-ribosyl cyclase family, i.e., Aplysia ADP-ribosyl
cyclase (Prasad et al., 1996) and human bone marrow stromal
cell antigen 1 (BST-1/CD157) (Yamamoto-Katayama et al.,
2002). However, the three proteins differ from each other in
terms of their membrane association. Aplysia ADP-ribosyl
cyclase is cytosolic, while BST-1 and CD38 are membrane-
bound via a glycosylphosphatidylinositol anchor and a trans-
membrane domain, respectively.
Biochemical and crystallographic analyses revealed that
Aplysia ADP-ribosyl cyclase and a soluble form of BST-1 exist
as dimers (Munshi et al., 1998; Sato et al., 1999). Interestingly,
however, the existence of a tetrameric form of human CD38
has been demonstrated (Bruzzone et al., 1998; Franco et al.,
1998; Mallone et al., 1998). Consistent with these reports,
a high molecular weight form of CD38, corresponding to a
tetramer, is induced by retinoic acid in human myeloid (HL-60)
leukemia cells (Umar et al., 1996). It was suggested that the
oligomerization is relevant to the catalytic activity of CD38 from
porcine heart microsomes (Chidambaram et al., 1998). The
orientation of the C-terminal a helix (a9) of human CD38 in the
crystal is distinct from those of the other two members (Liu
et al., 2005), so that the a9 helices would clash if two CD38
molecules formed a dimer in the same manner as the other two1586 Structure 20, 1585–1595, September 5, 2012 ª2012 Elsevier Ltd All rights reservedmembers (Figure S3B available online).
Thus, CD38 may have a distinct homo-
philic interaction mode that enables
tetramer formation on the cell surface.
However, the structural aspects of CD38
assembly and their functional importance
have not been elucidated thus far.
In the present study, we investigated
the mechanism and the role of CD38assembly. First, a crystallographic analysis of the extracellular
domain of mouse CD38 revealed two interaction modes, whose
combination allows the tetramerization of CD38 via a dimer-of-
dimers assembly. Second, both interaction modes were actually
found for cell-surface CD38 by a site-specific crosslinking exper-
iment using an expanded genetic code. Third, the two interaction
modes are both required for the catalytic activity and the target-
ing of mouse CD38 into membrane rafts. Accordingly, the
present study provides the structural basis for the tetrameriza-
tion of CD38 on the cell surface and demonstrates that the tetra-
merization of mouse CD38 is crucial for its multifaceted actions.
RESULTS
Novel Homophilic Interaction Modes of Mouse CD38
Deduced from the Crystal Packing of the Extracellular
Domain
The full-length extracellular domain of mouse CD38 exists as a
homodimer in solution, as revealed by analytical ultracentrifuga-
tion and size exclusion chromatography (Figure 1 and Figure S1).
However, the homophilic interaction modes of CD38 were not
suggested by the previous structural analysis of the full-length
extracellular domain of human CD38, since the two molecules
in the crystallographic unit lacked an apparent homodimer inter-
face (Liu et al., 2005). In the present study, during the preparation
of the extracellular domain of mouse CD38, we noticed that the
protein was partially cleaved at F288, causing the truncation of
16 amino acid residues from the C terminus, representing half
of the C-terminal a helix (Figure 2A). Thus, the crystal structure
of the C-terminal-truncated extracellular domain was solved
Figure 2. The Crystal Structure of the C-
Terminal Truncated Extracellular Domain
of Mouse CD38
(A) Sequence alignment between the extracellular
domains of the human and mouse CD38 proteins.
The truncation in mouse CD38 is underlined. The
glycosylation sites were mutated. Catalytically
important amino acid residues are boxed. The
amino acid residues involving the type I and type II
interfaces are indicated by black and pink bars,
respectively.
(B, C, E, and F) Structures of the extracellular
domain of the full-length human CD38, hCD38
(R48-I300) (B and E) and of the C-terminal
truncated mouse CD38, mCD38mut(R48-F288)
(C and F).
(D and G) Superimposition of the structures of
hCD38(R48-I300) (green) and mCD38mut(R48-
F288) (purple).
(H) An expanded view of the active sites. Cyclic
inosine diphosphate-ribose is colored orange
(2PGJ). See also Figure S2.
Structure
Tetramerization of CD38 on the Cell Surface(accession code 2EG9; Table 1 and Figure 2) and four types of
interfaces (I-IV) were found in the crystal packing (Figure 3).
The extracellular domain of CD38 with the C-terminal trunca-
tion also existed as a dimer in solution (Figure 1). The overall
structure was not significantly altered by the truncation, based
on the circular dichroism spectra (Figure S2). The crystal struc-
ture of the full-length extracellular domain of human CD38
(Liu et al., 2005) is divided into the N-domain (b1, a1, a2, a3,
a5, b3, and a6) and the C-domain (b2, a4, b4, a7, b5, a8, b6,
and a9). As shown in Figure 2, the crystal structure of the
C-terminal-truncated extracellular domain of mouse CD38
revealed that the a helices (a1, a2, a3, a5, and a6) of the
N-domain all superimposed well on those in the full-length extra-
cellular domain. The two a helices (a7 and a8) and the three-
stranded parallel b sheet (b4, b5, and b6) remain intact in the
C-domain, and they are only slightly tilted, as compared with
those in the full-length extracellular domain.Structure 20, 1585–1595, September 5, 2012 ªOn the other hand, the a9 helix was
entirely disordered, although the amino
acid residues corresponding to half of
the a9 helix still remained (Figure 2A). In
addition, the region corresponding to
the a4 helix of the full-length extracel-
lular domain was also disordered (S130–
M146) in the C-terminal-truncated form.
Thus, the most notable consequence of
the C-terminal truncation is the loss of
the a9 helix and the fluctuation of the
a4 helix.
The a1 helix exists at the type I inter-
face. The a4 helix, which was not fully
chain-traced, is actually located at the
type III interface (Figure 3H). The edge
of the a1 helix is in contact with the loop
region between the b5 strand and the a8
helix at the type III interface. Although
the type II interface between the a2 helixand the loop region between the b5 strand and the a8 helix by
itself is too small to connect two CD38 molecules (Figure 3E), it
may contribute to the oligomerization.
Based on the superimposition of the full-length extracellular
domain of human CD38, the a4 and a9 helices are both located
at the type III interface (Figure 3H). In this situation, the area of
the type III interface is calculated to be 1473 A˚2. It is unlikely that
the type IV interface exists in the cell-surface CD38, since the
glycosylation precludes this interaction, as described below (Fig-
ure 6C). The combination of the type I and type II/III interfaces
appears to cooperatively function in tetramer formation and is
compatible with membrane association (Figure 6).
At the type I interface, hydrophilic interactions (D64,R69/
R69,D64 and Q75,Q75) and hydrophobic interaction (D67,I72/
I72,D67 and L71,L71) are formed between the a1 helices (Fig-
ure 3D). Hydrophilic interactions between Q87 and Y283 and
between K94 and E251 are present at the type II interface2012 Elsevier Ltd All rights reserved 1587
Table 1. X-Ray Data Collection and Refinement Statistics
Data Collection
Wavelength (A˚) 1.0
Resolution (A˚) 50-2.8 (2.90-2.80)
Unique reflections 11912
Redundancy 4.9
Completeness (%) 97.9 (95.5)
I / s(I) 11.6 (5.2)
Rsym
a (%) 9.8 (22.6)
Refinement
Resolution (A˚) 49.12-2.80
No. of reflections 11873
No. of protein atoms 3390




rmsd bond length (A˚) 0.006
rmsd bond angles () 1.1
All numbers in parentheses represent last outer shell statistics.
aRsym = S jIavg-Iij / SIi, where Ii is the observed intensity and Iavg is the
average intensity.
bRfree is calculated for 10% of randomly selected reflections excluded
from refinement.
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Tetramerization of CD38 on the Cell Surface(Figure 3G). These amino acid residues are either conserved or
semi-conserved between mouse and human CD38 (Figure 2A).
Thus, it is conceivable that the type I and type II interfaces are
also possible for human CD38. Actually, an interface similar to
type I was previously reported by Shi et al., in the crystal struc-
ture of the full-length extracellular domain of human CD38
(1ZVM), as shown in Figure S3C.
In the present study, the full-length extracellular domain of
mouse CD38 was not successfully crystallized. For the crystallo-
graphic analyses, the glycosylation sites within the proteins were
mutated as usual to avoid chemical heterogeneity. The nongly-
cosylated, full-length mouse CD38 forms a large, amorphous
aggregate, probably due to the artificial interface IV, in addition
to the three interfaces (types I-III). In contrast, the C-terminal
truncation may have facilitated efficient crystal growth by
avoiding amorphous aggregation through the weakening of the
type III interface.
The Type I Interaction Mode of the Extracellular Domain
of CD38 Is Involved in Dimer Formation
The G68E mutation in the a1 helix reduces the stability of the ho-
mophilic interaction ofmouseCD38, expressed in amurine pro B
cell-derived cell line (Ba/F3 cells), after solubilization (Moreno-
Garcı´a et al., 2004). Here, the isolated extracellular domain
with the G68E mutation was shown to be present as a monomer
in solution by analytical ultracentrifugation and size exclusion
chromatography (Figure 1 and Figure S1). According to the
crystal structure, the G68E mutation should disrupt the type I
interface (Figure 3D). Thus, the results support the interaction
between the a1 helices of the extracellular domain of CD38 in
solution (the type I interaction mode).1588 Structure 20, 1585–1595, September 5, 2012 ª2012 Elsevier LtThe full-length mouse CD38 on the cell surface was cross-
linked by a membrane-impermeable, Lys-reactive chemical
crosslinker, BS3 (Moreno Garcı´a et al., 2004). Actually, BS3 treat-
ment of the isolated extracellular domain of CD38 also converted
it to a crosslinked dimer, which was abolished by the G68E
mutation (Figure 1C). If the BS3-crosslinking occurs via the
type I interaction mode, then the candidate for the crosslinked
site is Lys60-Lys60 (Figure S1). However, although trypsin
does not cleave CD38 at the Lys residue that reacted with
BS3, efficient cleavage at Lys60 was detected when the tryptic
fragments of the crosslinked dimer were analyzed bymass spec-
troscopy (Figure S1). Thus, it is unlikely that the BS3-dependent
crosslinking occurs via the type I interaction mode.
In the absence of the BS3-treatment, the extracellular domain
of CD38 with the C-terminal truncation eluted after the full-length
extracellular domain during size exclusion chromatography,
probably due to its smaller size (Figure 1B). However, the extra-
cellular domains with and without the truncation eluted at the
same position after the BS3-dependent crosslinking, suggesting
that the exposure of the C-terminal region to the solvent is
avoided and thedifference in the hydrodynamicproperty is coun-
teracted by the crosslinking. In addition, the cleavage at Lys145
in the a4 helix was decreased when the crosslinked dimer was
analyzed (Figure S1), implying that the BS3-dependent intermo-
lecular crosslinked via the type III interaction mode. Therefore,
the dimer of the extracellular domains of CD38, formed via the
type I interaction mode, is further considered to exist in equilib-
rium to form a tetramer via the type II/III interaction mode, within
which the intermolecular BS3-crosslinking occurs (Figure 3L).
The Homophilic Interaction of CD38 on the Cell Surface
The BS3-dependent intermolecular crosslinking of cell-surface
CD38 was impaired by the G68E mutation and by the C-terminal
truncation in A20 cells (Figures 4A and 4B). In addition, the loss of
the conserved disulfide bridge, which stabilizes the C-terminal
helix (C291A/C300A) (Figure 4C), reduced the intermolecular
crosslinking (Figures 4D and 4E). It should be noted that cova-
lently linked CD38 dimers were observed, even in the absence
of BS3, in the cases of the C291A and C300A mutations.
Conceivably, the C-terminal helices can contact each other to
permit the formation of artificial intermolecular disulfide bridges
between Cys300-Cys300 and Cys291-Cys291 when the original
disulfide bridge is disrupted and these residues lose their intra-
molecular partners. These results suggested that the C-terminal
helix and the a1 helix are involved in the homophilic interaction of
CD38 on the membrane, which supports the type I and type III
interaction modes.
To confirm that the type I and type III interaction modes are
actually involved in the CD38 assembly on the cell surface, a
photo-reactive crosslinker, p-benzoyl-L-phenylalanine (pBpa),
was separately introduced into CD38 at a defined position, ac-
cording to the method of Hino et al. (Hino et al., 2005, 2006).
Among the 14 variants designed to evaluate the interfaces, three
variants, with pBpa in place of V292 in the a9 helix and D64 or I65
in the a1 helix, were sufficiently expressed in Chinese hamster
ovary (CHO) cells and subjected to photo-crosslinking (Fig-
ure 5A). Crosslinked products with a molecular weight twice as
large as that of one CD38 molecule were formed for the CD38
variants with pBpa in place of V292, D64, and I65 (Figure 5B).d All rights reserved
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Figure 3. The Interfaces Involved in the
Homophilic Interaction of CD38
(A) The crystal packing of mCD38mut(R48-F288)
with asymmetric units (red) (2EG9).
(B, E, H, and J) Two molecules of the full-length
extracellular domain, hCD38(R48-I300), oriented
according to those in mCD38mut(R48-F288) (2EG9),
are shown. The monomer structure of
mCD38mut(R48-F288) (2EG9) was superimposed
(purple).
(C, F, I, and K) The four types of interfaces (I-IV) are
depicted with the accessible area and the shape
complementarities (in parentheses).
(D and G) Expanded views of the type I and type II
interfaces, respectively. Possible electrostatic (solid
lines) and hydrophobic (dashed lines) interactions
between the two a1 helices are shown in (D).
(L) The proposed dynamic equilibrium of the extra-
cellular domain of CD38 in solution. See also Fig-
ure S3.
Structure
Tetramerization of CD38 on the Cell SurfaceIn order to confirm that the crosslinked products represent
homophilic CD38 multimers, FLAG-tagged CD38 and Myc-
tagged CD38 were coexpressed in CHO cells. The crosslinked
products that were immunoprecipitated with the anti-FLAG
antibody reacted with both the anti-FLAG and anti-Myc anti-
bodies (Figures 5C and 5D, respectively). Thus, the results indi-
cated that the crosslinking occurs between CD38 molecules
and at least the a9 and a1 helices are near the interface. The
detection of the products corresponding to the tetramer
(Figures 5C and 5D) suggested that tetramerization of CD38
occurs on the cell surface and that the tetramer appears to
be more stable than the isolated extracellular domain in
solution.
The Processing of the N-Glycan of CD38 Is Compatible
with Tetramerization
During protein synthesis, oligomannose glycans are first pro-
cessed by a-glucosidases and mannosidases in the endo-Structure 20, 1585–1595, September 5, 2012plasmic reticulum and then are further
processed to complex- or hybrid-type
oligosaccharides by N-acetylglucosami-
nyltransferase I in the medial-Golgi (Fig-
ure S5A) (Kato and Kamiya, 2007). An
analysis of the site-specific glycan of
CD38 unexpectedly revealed that only
the oligosaccharides attached to the
N213 residue remained as the high-
mannose-type (Figure S5B). Within the
CD38 tetramer, the N213 residue faces
the space between the extracellular
domain and the membrane (Figure 6E).
This orientation would prevent the access
of the processing enzymes. By contrast,
the N213 residue is fully accessible to the
enzymes when CD38 is present as a dimer
or a monomer. Accordingly, the high-
mannose-type oligosaccharides of theN213 residue are indicative of the tetramerization of CD38 during
the processing of the N-glycan.
The Two Interaction Modes Are Crucial for the Catalytic
Activity of CD38
Among the ADP-ribosyl cyclase family proteins, the catalytically
important residues, W125, E146, W189, and E226 in human
CD38, are located at spatially equivalent positions (Liu et al.,
2005; Prasad et al., 1996; Yamamoto-Katayama et al., 2002).
In the sequence, W125 and E146 are located near the a4
helix (boxed in Figure 2A). As shown in Figure 2H, the posi-
tions of W129 and E230 in the C-terminal-truncated extracel-
lular domain of CD38 (shown in purple) were shifted by approx-
imately 3 A˚ as compared to the corresponding residues, W125
and E226, in the full-length extracellular domain (shown in
green). This displacement suggests the importance of the
proper interaction between the C-terminal a9 helix and the a4
helix in catalytic-site formation, which is consistent with theª2012 Elsevier Ltd All rights reserved 1589
Figure 4. The C-Terminal and Juxtamembrane a Helices Are Both
Important for the Homophilic Interaction of CD38 on the Cell Surface
and the Catalytic Activity
(A and D) A20 cells (1 3 107 cells/ml) transfected with glycosylated or non-
glycosylated FLAG-tagged CD38 in either the FL or truncated form or with the
indicated mutations were incubated in the absence or presence of BS3. The
proteins were detected by immunoblotting with a biotin-anti-FLAG pAb, as
described in the Supplemental Experimental Procedures. The positions of the
crosslinked dimers and the noncrosslinked monomers of CD38 are shown by
triangles and arrows, respectively.
(B and E) The crosslinking ratios, which are the intensities of crosslinked dimer
to noncrosslinked monomer in Figures 7A and 7D, respectively, are expressed
as relative values to that without the truncation. Densitometric analysis was
performed using the ImageJ software (http://rsbweb.nih.gov/ij/).
(C) Sequence alignment of the C-terminal regions of human and mouse CD38
and schematic representations of the FLAG-tagged mouse CD38 constructs
to probe the roles of the C-terminal a-helix. The two conserved cysteine
residues involved in the disulfide bridge (Cys287 and Cys296 in human CD38
and Cys291 and Cys300 in mouse CD38) are also shown.
(F and G) NAD+ glycohydrolase activities of A20 cells (none) or CD38 trans-
fectants without (FL) and with the C-terminal truncation or the mutations were
measured. Significant differences are indicated: ** = p < 0.01; n.s. = not
significant (p > 0.05). Values are means ± SD (n = 3). See also Figure S4.
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1590 Structure 20, 1585–1595, September 5, 2012 ª2012 Elsevier Ltresults previously reported for calcium-loaded CD38 (Liu et al.,
2008).
In the case of the isolated extracellular domain, both the
C-terminal truncation of 16 amino acid residues and the
G68Emutation appreciably decreased the NAD+ glycohydrolase
activity (Figure S4E). In addition, the BS3-crosslinking and the
specific activity of the NAD+ glycohydrolase were decreased
at a lower concentration of the extracellular domain (Figures
S4F and S4G), implying that proper assembly is important for
the catalytic activity of CD38 in solution.
In A20 cells, the C-terminal truncation of four amino acid resi-
dues did not affect the NAD+ glycohydrolase activity of CD38
(Figure 4F), which is consistent with the fact that the four resi-
dues are disordered in the crystal structure of human CD38
(Liu et al., 2005). However, the truncation of eight amino acid
residues appreciably reduced the NAD+ glycohydrolase activity.
This may be due to the loss of the disulfide bond between
Cys291 and Cys300, which is conserved among the family
proteins (Figure 4C), since the mutations affecting the disulfide
bond appreciably reduced the catalytic activity (Figure 4G).
The truncation of 16 and 20 amino acid residues resulted in the
complete loss of the NAD+ glycohydrolase activity. The cyclase
activity was also diminished by the truncation of 16 amino acid
residues (Figure S4D). Thus, the C-terminal region involving the
type III interaction mode is crucial for the catalytic activity.
The G68E mutation in the a1 helix abolished the NAD+ glyco-
hydrolase activity of CD38 in A20 cells (Figure 4G). The effect
was comparable to that of themutation of the catalytically impor-
tant Glu150 to Leu (E150L). A consistent result was previously
obtained in Ba/F3 cells (Moreno-Garcı´a et al., 2004). Since the
G68E mutation disrupts the homophilic interaction (Figure 1
and Figure S1) and Gly68 participates in the type I interaction
mode (Figure 3), it is suggested that the integrity of the type I
interaction mode is necessary for the catalytic activity of CD38
on the cell surface. Accordingly, the two interaction modes are
both crucial for the catalytic activity.
The Two Interaction Modes Facilitate the Association
of CD38 with Detergent-Resistant Membranes
Biochemical analyses have revealed the specific associations of
several membrane proteins with detergent-resistant membranes
(DRMs). DRMs are enriched in cholesterol and sphingolipids and
can be isolated as low-density fractions from detergent-lysed
cells (Brown and Rose, 1992). Although membrane rafts and
DRMs should be carefully distinguished (Sonnino, 2008),
DRMs can reflect important changes in the distribution of
proteins on the membranes.
As shown in Figure 7A, CD38 was recovered in DRMs after
A20 cells expressing CD38 were lysed with 1% Brij-58. The
amounts of CD38 in DRMs were decreased by the G68E
mutation in the a1 helix and by the C-terminal truncation
(Figures 7B and 7C). We previously reported that the ligation of
CD38 with the agonistic antimouse CD38 antibody, CS/2,
increased the association of CD38 with DRMs in mouse splenic
B cells (Hara-Yokoyama et al., 2008). The amount of wild-type
CD38 in DRMs was further increased by treating A20 cells with
CS/2. However, the amount of truncated CD38 in DRMs was
not significantly increased byCS/2, although theC-terminal trun-
cation did not reduce the binding of CS/2 to CD38 (Figure S6).d All rights reserved
Figure 5. Site-Specific Crosslinking of
Cell-Surface CD38
(A) The residues to which the crosslinker was
introduced are shown in hCD38(R48-I300) in two
perpendicular views.
(B–D) CHO cells were transfected with amber
mutants of FLAG-tagged CD38 (B) or with both
FLAG-tagged and Myc-tagged CD38 (C and D).
Light-dependent crosslinking of CD38 was
performed as described in the Experimental
Procedures. The reaction was analyzed by
immunoblottingwith an anti-FLAG antibody (B and
C) and an anti-Myc (D) antibody.
Structure
Tetramerization of CD38 on the Cell SurfaceThese results suggest that the two interaction modes contribute
to the association of CD38 with DRMs.
In addition, we examined whether the C-terminal truncation
affects the lipid composition of DRMs harboring CD38 (CD38-
DRMs) by the immunoprecipitation of CD38 in DRMs. In this
context, CD38 has an affinity for sphingolipids, as the catalytic
activities of CD38 are inhibited by gangliosides (Hara-Yokoyama
et al., 1996, 2001). In the CD38-DRMs, lipids were similarly
detected with and without the C-terminal truncation, regardless
of the CS/2 stimulation and glycosylation (Figure S6). Accord-
ingly, it is unlikely that the C-terminal truncation alters the lipid
composition in CD38-DRMs.
Functional Aspects of N-Glycosylation of CD38
CD38 has four potential N-glycosylation sites (Gao and Mehta,
2007). We compared the wild-type and mutant CD38 proteins,
in which the Asn residues were mutated to Asp residues
(N104D/N124D/N213D/N223D), to evaluate the role of the
N-glycosylation. Even in the absence of glycosylation, the
C-terminal truncation reduced the BS3-dependent crosslinkingStructure 20, 1585–1595, September 5, 2012 ª(Figures 4A and 4B) and abolished the
catalytic activity (Figure S4). However,
the truncation did not alter the amount
of nonglycosylated CD38 in DRMs in
both the presence and absence of CS/2
(Figures 7D and 7E). Thus, the glycosy-
lated and nonglycosylated CD38 mole-
cules associated with DRMs in different
manners. Wewill discuss this point below
from the perspective of the involvement
of glycosylation in the regulation of the
cell-surface assembly of CD38.
DISCUSSION
In the present study, we demonstrated
that the type I and type II/III interaction
modes are involved in the assembly of
mouse CD38 on the cell surface. The
combination of the modes cooperatively
stabilizes the tetramer. The type I interac-
tion mode is primarily involved in the core
homophilic interaction between the
extracellular domains. The core dimer
formed via the type I interaction mode isthen assembled into the tetramer via the type II/III interaction
mode, which provides a structural basis for the previously re-
ported tetramerization. In the case of the extracellular domain,
the association/dissociation in the dimer-tetramer equilibrium
may be fast, and thus the tetramer was not detectable during
analytical ultracentrifugation and size exclusion chromatog-
raphy. Tetramerization occurs more efficiently with the full-
length CD38 on the cell surface than the extracellular domain
fragments in solution, probably because the orientation of the
extracellular domain is restricted on the cell surface. Since the
integrity of both interaction modes was required for the catalytic
activity and the raft-association ability of CD38, we conclude that
the tetramerization due to the dimer-of-dimers interaction is vital
for the functional aspects of CD38 on the cell surface. Further-
more, we discovered the role of glycosylation in the regulation
of the homophilic interaction of CD38. Thus, the assembly of
CD38 is distinct from those of the other family members,
although the structures of the protomers are well conserved
among them, except for the orientation of the C-terminal a-helix
(Liu et al., 2005).2012 Elsevier Ltd All rights reserved 1591
Figure 6. Schematic Representations of
the Dimer-of-Dimers Interactions of CD38
on the Cell Surface
The four molecules of hCD38(R48-I300) are
assembled by the type I interface (red oval) and
by the type II/III interfaces (blue oval), as in
mCD38mut(R48-F288) in the crystal (2EG9). The
structures in (D and E) are shown in a perpendic-
ular view to those in (A)–(C). The residues corre-
sponding to D64, I65, and V292 of mouse CD38
are depicted in red, and those corresponding to
C291 and C300 are yellow and light orange,
respectively (A). The catalytically important resi-
dues (W125, E146, W189, and E226 in hCD38) are
shown in red (B and D). (C and E) The structure of
the N-linked oligosaccharide moiety from a fat-
depleting factor (1ZAG), composed of nine sugar
residues, is attached to the residues correspond-
ing to the N-glycosylation sites of mouse CD38
(N104, N124, N213, and N223, respectively). See
also Figure S5.
Structure
Tetramerization of CD38 on the Cell SurfaceWithin the tetramer of CD38, the a9 helix can interact with the
a4 helix of the other CD38 molecule at the type III interface to
reciprocally stabilize each other’s active sites (Figure 6B). In
this context, the pair of the a9 and a4 helices is considered to
be a molecular device coupling the homophilic interaction to
the catalytic site formation. The requirement of the type I interac-
tion mode for the catalytic activity is explained by the stabiliza-
tion of the type II/III interfaces via tetramerization.
A long-lasting topological problem is how the catalytic activity
of the CD38 ectoenzyme is involved in intracellular calcium
signaling (Malavasi et al., 2008). The oligomerized CD38 report-
edly acts as a channel of cyclic ADP ribose (cADPR) (Franco
et al., 1998). Intriguingly, in the tetramer structure, all of the cata-
lytic sites face the space enclosed between the ectoenzyme and
themembrane surface (Figure 6D). It would be tempting to deter-
mine whether the four transmembrane domains in the tetrameric
assembly are the basis for the putative inward channel activity of
the produced cADPR.
The clustering of membrane proteins enhances their targeting
to membrane rafts (Hammond et al., 2005). The clustering of
T cell receptors (TCR), B cell receptors (BCR), and FcεRI, caused
by antigen/MHC complexes or oligomeric antigens, facilitates
their recruitment to membrane rafts and triggers immune-recog-
nition receptor signaling in T, B, and mast cells, respectively1592 Structure 20, 1585–1595, September 5, 2012 ª2012 Elsevier Ltd All rights reserved(Gupta and DeFranco, 2007; Jury et al.,
2007; Silveira E Souza et al., 2011). The
present study suggests that the raft-tar-
geting of CD38 requires its intrinsic clus-
tering on the cell surface rather than the
lipid interaction. The C-terminal and jux-
tamembrane helices of CD38 are
required, but the defect due to the
C-terminal truncation is not compen-
sated by the ligation with the agonistic
antibody. Therefore, the integrity of the
two modes of homophilic interactions
enabling tetramerization appears to be
essential. However, at present, we havenot succeeded in detecting the CD38 tetramer clearly after
SDS-PAGE. The tetramer is probably stabilized on the
membrane and readily dissociates to monomers or dimers in
the presence of detergent. A more sophisticated approach,
such as single-molecule tracking on live cells, will be required
to detect the tetrameric form on the cell surface. Additionally,
no partner molecule within membrane rafts that can generally
explain the raft-targeting of CD38 has been identified, although
the association of CD38 with the Src family protein tyrosine
kinase Lck has been reported (Cho et al., 2000). It is conceivable
that the identification of the CD38 partner would require experi-
mental conditions that maintain the integrity of the CD38
tetramer.
In contrast to the glycosylated CD38, the effect of the
C-terminal truncation on the association of CD38 with DRMs
was not observed in the absence of N-glycosylation. The
absence of the N-glycans attached to N104 and N223 is consid-
ered to enable the formation of the ‘‘type IV’’ interface (Figure 3K).
Actually, BS3-dependent high-molecular mass aggregates of
CD38 were observed in the absence of glycosylation. Similar
results were obtained in HeLa and Michigan Cancer Foundation
(MCF)-7 cells (Gao and Mehta, 2007). Thus, the N-glycans
probably regulate the assembly of CD38 on the cell surface by
inhibiting the ‘‘aggregating’’ type IV interface.
Figure 7. The C-Terminal Region Truncation and the G68E Mutation
Decrease the Association of Glycosylated CD38 with DRMs
(A) A20 cells transfected with glycosylated FLAG-tagged CD38 (2 3 108
cells/ml), without (FL) and with the G68E mutation, were lysed in 1% Brij-58
lysis buffer.
(B and D) A20 cells transfected with glycosylated (B) and nonglycosylated (D)
FLAG-tagged CD38 (23 108 cells/ml) in either the full-length (FL) or truncated
form were stimulated with 20 mg/ml CS/2 and then lysed. Lysates were
fractionated by sucrose density gradient ultracentrifugation, as described in
the Supplemental Experimental Procedures. Proteins in the DRM and bottom
fractions were separated by 10% SDS-PAGE and were detected by immu-
noblotting with a biotinylated anti-FLAG pAb and an anti-Lyn pAb. Essentially,
the same results were obtained in an independent experiment.
(C and E) The intensities of the bands in (B and D) were quantified and
expressed as the relative values to that without the truncation (FL) in the
absence of CS/2. Densitometric analysis of the band intensity was performed
using the ImageJ software. Values are means ± SD (n = 3). Significant differ-
ences are indicated: ** = p < 0.01; * = p < 0.05; n.s. = not significant (p > 0.05).
See also Figure S6.
Structure
Tetramerization of CD38 on the Cell SurfaceRecently, the mono N-glycosylated forms of bovine CD38
have been revealed as parallel ‘‘back-to-back’’ homodimers
(Egea et al., 2012), which would not be allowed in the case of
mouse CD38 due to the glycosylation at N124. Thus, the
assembly of CD38 might have diversity among species.
From a clinical point of view, CD38 is recognized as a negative
prognostic indicator in B cell chronic lymphocytic leukemia
patients and in individuals infected with HIV (Malavasi et al.,
2008). Based on studies using B cell chronic lymphocyticStructure 20, 1585–15leukemia cells, CD38 is a potential signaling molecule that regu-
lates cell fate rather than a mere marker (Malavasi et al., 2008).
Autoantibodies against CD38 reportedly impaired glucose-
induced insulin secretion in a noninsulin-dependent diabetes
patient (Ikehata et al., 1998). Considering the functional impor-
tance of the cell-surface assembly of mouse CD38 demon-
strated here, the assembly of human CD38 should be resolved
to develop a new therapeutic strategy, in which the disassembly
of CD38 can be manipulated.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The extracellular domains of CD38 were transiently expressed as secreted
proteins in Drosophila S2 cells and purified as described previously (Hara-
Yokoyama et al., 2008). Plasmid construction is described in the Supplemental
Experimental Procedures. For the crystallization, the four Asn residues were
mutated to Asp residues (N104D, N124D, N213D, and N223D).
Crystallization and Data Collection
The crystallization screening of FLAG-mCD38mut(R48-F288) was performed
by the sitting-drop vapor diffusion method (protein at 7.4 mg/ml) at 20C.
Diffraction quality crystals were grown by the addition of 0.2 M NDSB-256
(Hampton Research) to the sitting drops, which were equilibrated against
a reservoir solution containing 25% polyethylene glycol 1500 (PEG1500).
The crystals belonged to the primitive orthorhombic space group P21212,
with unit cell constants of a = 59.1 A˚, b = 176.8 A˚, c = 44.6 A˚, and contained
two CD38 molecules per asymmetric unit. Single crystals were coated with
Paratone-N and 10% glycerol, mounted using a nylon loop (Hampton
Research), and flash-cooled in the cold stream of the goniometer. The data
were collected with a wavelength of 1.0 A˚ on beamline BL26B2 at SPring-8
(Harima, Japan) and were recorded on a Jupiter210 charge-coupled device
detector (Rigaku). The diffraction data were processed with the HKL2000
program (Otwinowski and Minor, 1997).
Structure Determination and Refinement
The structure of FLAG-mCD38mut(R48-F288) was determined by molecular
replacement with the program MOLREP (CCP4), using human CD38 (PDBID:
2DF1) as the searchmodel. Themodel was corrected iteratively using O (Jones
et al., 1991), and structure refinement was performed using Crystallography
and NMR system (Bru¨nger et al., 1998). Refinement statistics are presented
in Table 1. The quality of themodel was inspected by the programPROCHECK
(Laskowski et al., 1993). Graphic figures were created using the program
PyMOL (http://www.pymol.org). The atomic coordinates have been deposited
in the Protein Data Bank, with the accession code 2EG9.
Cells
The murine B lymphoma-derived cell line A20 and the CHO cells were main-
tained in Roswell Park Memorial Institute 1640 medium supplemented with
8% fetal bovine serum and 50 mM 2-mercaptoethanol and in minimum essen-
tial medium supplemented with 10% fetal bovine serum, respectively. Both
media contained penicillin and streptomycin.
Stable Transfectants
Plasmid construction is described in the Supplemental Experimental
Procedures. Transfection of A20 cells was performed using the Nucleofector
technology (Amaxa), and puromycin-resistant cells were obtained.
Site-Specific Crosslinking
The CD38 gene in pCEpuro-mCD38-T304 was mutagenized to create an
amber codon located at H61, D64, I65, L67, R69, L71, L77, L135, L137,
T140, W141, I142, P285, or V292. Each amber mutant CD38 gene (5 mg
DNA) was cotransfected into CHO cells (5 3 106 cells) with pcpBpaRS ver.1
(5 mg DNA), carrying the bacterial pair of an amber suppressor transfer RNA
(tRNA) and an aminoacyl-tRNA synthetase specific to p-benzoyl-L-phenylala-
nine (pBpa) (Hino et al., 2005, 2006), using Lipofectamine 2000 (36 ml). Among95, September 5, 2012 ª2012 Elsevier Ltd All rights reserved 1593
Structure
Tetramerization of CD38 on the Cell Surfacethe mutants, the protein was sufficiently expressed in the presence of pBpa
when the amber codon was introduced at positions D64, I65, and V292 after
overnight culture. The cells were then exposed to UV light and lysed with
1% Triton X-100 in buffer A, consisting of 20 mM Tris-HCl, 150 mM NaCl,
10 mM iodoacetamide, 2.5 mM NaF, 2.5 mM sodium pyrophosphate,
10 mM ethylenediaminetetraacetic acid, 10 mM b-glycerophosphate, 1 mM
sodiumorthovanadate, 1mMphenylmethylsulfonyl fluoride, 5 mg/ml leupeptin,
10 mg/ml pepstatin, and 10 mg/ml aprotinin, pH 7.5. Cell lysates were incubated
for 2 hr at 4C with a 10 ml slurry of anti-FLAG M2 agarose resin. After the resin
was washed, the complexes were eluted with 100 mg/ml FLAGx3 peptide and
analyzed by immunoblotting.
Statistical Analysis
Differences between mean values were assessed by the Student’s t test. The
statistical significance was set at P less than .01 or .05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/
10.1016/j.str.2012.06.017.
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